GC Genome's Third-Quarter Operating Profit Rises 12.5% ... Sixth Straight Quarter in the Black
- Input
- 2026-11-16 15:34:23
- Updated
- 2026-11-16 15:34:23

GC Genome said on the 16th that it recorded revenue of 8.9 billion won and operating profit of 900 million won in the third quarter of this year. These figures were up 1.1% and 12.5%, respectively, from the same period last year. Compared with the previous quarter, revenue rose 7.2% and operating profit increased 125%. Both revenue and operating profit were the highest ever for a third quarter.
Cumulative revenue through the third quarter of this year reached 24.7 billion won, up 5.1% from the same period last year. Operating profit over the same period rose 37.6% to 1.4 billion won. Operating profit growth was at least seven times the revenue growth rate, highlighting a marked improvement in profitability.
Key testing products drove the results, including G-NIPT, a noninvasive prenatal test, and ai-CANCERCH, a multi-cancer early detection screening test. Revenue increased across existing businesses, including obstetric, cancer, and genetic rare-disease testing.
The company also expanded its financial capacity. Cash holdings at the end of the third quarter totaled 41.8 billion won, up from about 40 billion won at the end of last year. Its strategy is to invest in research and development and overseas market entry, drawing on cash generated from its stable domestic operations.
GC Genome is pursuing an expansion of the cancer types screened by ai-CANCERCH and developing follow-up tests, while also exploring overseas expansion for G-NIPT. It plans to expand its overseas business, including by seeking Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for ai-CANCERCH to support entry into the U.S. market.
[email protected] Jung Sang-hee Reporter